ABT Hits The Right Note, AVXS Walks The Talk, STEM Splits, LJPC Awaits Data

AveXis Inc.'s (AVXS) ongoing phase I trial of drug candidate AVXS-101 in spinal muscular atrophy Type 1 patients continues to demonstrate a favorable safety profile.

from RTT - Biotech http://ift.tt/1rJ3qch
via IFTTT